WO1997001337A1 - Combinaison d'antihistamines et de steroides a application topique par voie nasale - Google Patents

Combinaison d'antihistamines et de steroides a application topique par voie nasale Download PDF

Info

Publication number
WO1997001337A1
WO1997001337A1 PCT/US1996/010789 US9610789W WO9701337A1 WO 1997001337 A1 WO1997001337 A1 WO 1997001337A1 US 9610789 W US9610789 W US 9610789W WO 9701337 A1 WO9701337 A1 WO 9701337A1
Authority
WO
WIPO (PCT)
Prior art keywords
nasal
topical
triamcinolone
flunisolide
constitutes
Prior art date
Application number
PCT/US1996/010789
Other languages
English (en)
Inventor
Eileen Helzner
Original Assignee
Mcneil-Ppc, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mcneil-Ppc, Inc. filed Critical Mcneil-Ppc, Inc.
Priority to AU63924/96A priority Critical patent/AU6392496A/en
Publication of WO1997001337A1 publication Critical patent/WO1997001337A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Definitions

  • the present invention relates to prevention and treatment of the symptoms of seasonal and perennial allergic rhinitis. More particularly, the present invention relates to the prevention and treatment of the symptoms of seasonal and perennial allergic rhinitis by the application of a combination of topical nasal antihistamines and topical nasal steroids.
  • rhinitis is most frequently caused by pollen, pollen fragments and mold spores.
  • the airborne pollens, pollen fragments and mold spores are deposited on the nasal mucosa.
  • rhinitis symptoms develop which include puffy, sore eyes, sneezing, nasal congestion, sinus headaches and fatigue.
  • perennial allergic rhinitis The chronic symptoms of perennial allergic rhinitis are most frequently caused by reaction to perennial allergens, such as, house dust mite, mold, cockroach, animal saliva, urine, and dander.
  • perennial allergens such as, house dust mite, mold, cockroach, animal saliva, urine, and dander.
  • the symptoms resemble those of seasonal allergic rhinitis but the duration is year round or episodic depending upon the source of the allergens.
  • Antihistamines are the primary medicaments employed to treat allergic rhinitis. Antihistamines are helpful to control sneezing, itching, and rhinorrhea as well as associated ocular symptoms but are ineffective in relieving nasal blockage. Antihistamines compete with histamine for binding to Hi receptors and thereby prevent the action of histamine which includes bronchospasm, edema, increased mucus secretion and itching.
  • the antihistamines primarily in use today are orally active and administered.
  • intranasally (topically) administered antihistamines including azelastine and levocabastine have also been shown to be useful antihistamines in the treatment of allergic rhinitis.
  • the intranasally administered antihistamines have a quick onset of action because they are delivered directly to the site of activity.
  • nasal steroids particularly the corticosteroids.
  • Such steroids have powerful effects on immunologic and hormonal processes and are very effective in treating the inflammation which accompanies the allergic reaction.
  • Suitable nasal steroids known in use today include beclamethasone, flunisolide, triamcinolone, dexamethasone and budesonide.
  • a nasal spray or nasal drops for the treatment of allergic rhinitis comprising:
  • topical nasal antihistamine to relieve histamine mediated symptoms
  • topical nasal antihistamine is selected from the group consisting of levocabastine, azelastine and azatadine
  • nasal steroid selected from the group consisting of beclomethasone, flunisolide, triamcinolone, dexamethasone and budesonide; and
  • the topical antihistamines herein are potent H 1 receptor antagonists which relieve the histamine mediated symptoms, i.e. sneezing, runny nose, itchy nose, etc.
  • the H 1 receptor antagonists block the receptor sites and thereby block the expression of the histamine effect.
  • levocabastine from about 0.05 to about 10 mg and preferably from about 0.5 to about 5 mg should be administered in this combination every 4 to 12 hours.
  • azelastine from about 0.05 to about 10 mg and preferably from about 0.5 to about 5 mg should be administered in this combination every 4 to 12 hours.
  • azatadine from about 0.05 to about 10 and preferably from about 0.5 to about 5 mg should be administered in this combination every 4 to 12 hours.
  • levocabastine should constitute of the nasal spray or nasal drops composition from about 0.2 to about 40 mg/ml and preferably from about 2 to about 20 mg/ml.
  • azelastine should constitute of the nasal spray or nasal drops composition from about 0.2 to about 40 mg/ml and preferably from about 2 to about 20 mg/ml.
  • azatadine should constitute from about 0.2 to about 40 mg/ml and preferably from about 2 to about 20 mg/ml.
  • Levocabastine as used herein included e s levocabastine and its pharmaceutically acceptable acid addition salts. Suitable salts include the hydrochloric, hydrobromic, sulfuric, nitric, acetic, propionic, butanedioic, etc. salts. The preferred salt is hydrochloric.
  • Levocabastine, (-)-[3S-1 (cis),3,4]-1- [4-cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenyl-4-piperidine carboxylic acid is a well known compound and may be prepared by the method of U.S. Pat. 4,369,184, EP 34,415 or Stokbroekx, R. A., et al., Drug Dev. Res. 8: 87-93 (1986).
  • Azelastine as used herein includes azelastine and its pharmacutically acceptable salts.
  • Preferred are the acid addition salts, such as, the hydrohalo salts and salts with organic acids.
  • Preferred salts include hydrochloridic hydrobromidic, embonic acid, maleic acid, citric acid and tartaric acid salts.
  • Azelastine, 4-(p-chlorobenzyl)-2-[N-methyl-perhydroazepin-4-yl)-1-(2H)- phthalazinone, is a well known compound and may be prepared according to Belg. Pat. 778,269; Vogelsang et al., U.S. Pat. 3,813,384 and Scheffler et al., Arch. Pharm. 321 , 205 (1988).
  • Azatadine as used herein includes azatadine and its pharmaceutically acceptable salts.
  • Preferred salts of azatadine include its maleate, sulfate, succinate and acetate salts.
  • Aztadine, 4-aza-5-(N-methyl-4-piperidinylidene)- 10,11-dinydro-5H-dibenzo[a,d]cycloheptene is a well known compound and may be prepared according to Belg. Pat. 647,043; U.S. Pat. 3,3577,986 and Villani et al., J. Med. Chem. 15, 750 (1972).
  • the topical nasal steroids for use herein are corticosteroids which inhibit the release of mediators for the symptoms associated with allergic rhinitis from mast cells and basophils. They also reduce inflammation and suppress neutrophil chemotaxis.
  • the topical nasal steroids herein have relatively few side effects but are known to cause nasal irritation, drying and epistaxis with use of nasal sprays.
  • persons skilled in the art understand that only a sufficient amount of nasal steroid should be administered to inhibit mast cell mediator release and inflammation and no more. This amount will vary depending on whether beclomethasone, flunisolide, triamcinolone, dexamethasone or budesonide is employed.
  • the nasal steroids are relatively long acting and alone can be administered once or twice daily.
  • the amount of nas? 1 steroid when used in conjunction with an active ingredient requiring more frequent administration, the amount of nas? 1 steroid must be adjusted accordingly.
  • beclomethasone from about 10 to about 100 meg, and preferably from about 15 to about 85 meg should be administered in this combination every 4 to 12 hours.
  • the beclomethasone should constitute of the nasal spray or nasal drops composition from about 0.05 to about 0.5 mg/ml, and preferably from about 0.1 to about 0.3 mg/ml.
  • flunisolide from about 30 to about 300 meg, and preferably from about 50 to about 200 meg should be administered in this combination every 4 to 12 hours.
  • the flunisolide should constitute of the nasal spray or nasal drops composition from about 0.1 to about 1.0 mg/ml, and preferably from about 0.15 to about 0.5 mg/ml.
  • the triamcinolone from about 10 to about 100 meg, and preferably from about 15 to about 85 meg should be administered in this combination every 4 to 12 hours.
  • the triamcinolone should constitute of the nasal spray or nasal drops composition from about 0.05 to about 0.5 mg/ml, and preferably from about 0.1 to about 0.3 mg/ml.
  • dexamethasone from about 40 to about 400 meg, and preferably from about 60 to about 340 meg should be administered in this combination every 4 to 12 hours.
  • the dexamethasone should constitute of the nasal spray or nasal drops composition from about 0.2 to about 2.0 mg/ml, and preferably from about 0.4 to about 1.2 mg/ml.
  • the budesonide from about 40 to about 400 meg, and preferably from about 60 to about 340 meg should be administered in this combination every 4 to 12 hours.
  • the budesonide should constitute of the nasal spray or nasal drops composition from about 0.2 to about 2.0 mg/ml, and preferably from about 0.4 to about 1.2 mg/ml.
  • the corticosteroid topical nasal steroids are, as a general matter, poorly soluble in water.
  • the particles are administered in particulate form, as a micronized suspension in a suitable carrier/solvent system.
  • a suitable carrier/solvent system for the treatment of the lung, it is desirable to produce aerosol particle sizes of less than 3 microns.
  • the necessity of producing an aerosol of small particles is removed.
  • the particle size of the corticosteroid in suspension is not critical so long as the particle is small enough that the amount of compound available for therapeutic activity is not surface area limited and the particle is stable in suspension.
  • the suspension may be maintained with suitable liposomes.
  • solubilizing agents include 1 ,2-propane diol, 1 ,3-propane diol, polyethylene glycol having a molecular weight of 100 to 800, dipropylene glycol, or ethanol.
  • a suitable surfactant may be a pharmaceutically acceptable non-ionic, anionic or cationic surfactant.
  • non-ionic surfactants include glycerol fatty acid esters such as glycerol monostearate, glycol fatty acid esters such as propylene glycol monostearate, polyhydric alcohol fatty acid esters such as polyethylene glycol (400) monooleate, polyoxyethylene fatty acid esters such as polyoxyethylene (40) stearate, polyoxyethylene fatty alcohol ethers such as polyoxyethylene (20) stearyl ether, polyoxyethylene sorbitan fatty acid esters such as polyoxyethylene sorbitan monostearate or polysorbate 20, fatty acid ethanolamides and their derivatives such as the diethanoiamide of stearic acid, and the like.
  • glycerol fatty acid esters such as glycerol monostearate
  • glycol fatty acid esters such as propylene glycol monostearate
  • polyhydric alcohol fatty acid esters such as polyethylene glycol (400) monooleate
  • polyoxyethylene fatty acid esters such
  • Suitable anionic surfactants are soaps including alkali soaps, such as sodium, potassium and ammonium salts of aliphatic carboxylic acids, usually a fatty acids, such as sodium stearate.
  • Organic amine soaps also included, include organic amine salts of aliphatic carboxylic acids, usually fatty acids, such as triethanolamine stearate.
  • Another class of suitable soaps is the metallic soaps, salts of polyvalent metals and aliphatic carboxylic acids, usually fatty acids, such as aluminum stearate.
  • suitable cationic surfactants include amine salts such as octadecyl ammonium chloride, quartemary ammonium compounds such as benzalkonium chloride.
  • solubilizing agent and surfactant should be employed to stabilize the suspension/emulsion. Generally there should be employed from about 5 to about 30% w/v and preferably from 10 to about 25% w v of cosolvent. Likewise, there should be employed from about 0.1 to about 10% w/v and preferably from about 0.5 to about 5% w v of surfactant.
  • Beclamethasone as used herein includes beclamethasone, beclamethasone acetate, beclamethasone valerate, beclamethasone propionate, beclamethasone dipropionate and the like, including the hydrates thereof.
  • Beclamethose, 9-chloro-11 ,17,21-trihydroxy-16-methylpregna-1,4- diene-3,20-dione, may be obtained commercially and is prepared according to Brit. Pat. 912,378 and Brit. Pat. 901 ,093. Beclamethasone is commercially available.
  • Flunisolide as used herein includes flunisolide and flunisolide acetate and hydrates thereof.
  • Flunisolide, 6-fluoro-11 ,21-dihydroxy-16,17-[(1- methylethylidene)bis(oxy)]pregna-1 ,4-diene-3,20-dione, may be prepared using S. roseoc romogenes as in Brit. Pat. 933,867 and Chem. Abst. 60, 3070f (1964) or using Cunninghamella blakesleeana as in U.S. pat. 3,124,571. Flunisolide is also prepared in 4,273,710. Flunisolide is commercially available.
  • Triamcinolone as used herein includes triamcinolone and its 16- ⁇ , 21- diacetate; triamcinolone acetonide, and its 21 -acetate, 21 -disodium phosphate, and 21 -hemisuccinate; triamcinolone benetonide and triamcinolone hexacetonide, including hydrates thereof.
  • Triamcinolene, 9- fluoro-11,16,17,21 -tetrahydroxypregna-1 ,4-diene-3,20-dione may be prepared according to Bernstein et al., J. Am. Chem. Soc. 78, 5693 (1956) and 81, 1689 (1959); Thoma et al., J. Am. Chem.
  • Triamcinolone acetonide may be prepared by stirring a suspension of triamcinolone in acetone in the presence of a trace of perchloric acid.
  • Triamcinolone benetonide may be prepared according to Ger. Pat. 2,047,218 or U.S. Pat. 3,749,712.
  • Triamcinolone hexacetonide may be prepared according to U.S. pat. 3,457,348.
  • the triamcinolone and derivatives as taught herein have been sold or are available commercially.
  • Dexamethasone as used herein includes dexamethasone and its 21 - phosphate, 21 -acetate, 21 -phosphate disodium salt, 21- dimethylaminoacetate, 21-isonicotinate, 17,21-dipropionate and 21 -palmitate.
  • Dexamethasone, (11 ⁇ , 16 ⁇ )-9-f luoro- 11 ,17,21-trihydroxy-16-methylpregna- 1 ,4-diene-3,20-dione may be prepared according to Arth et al., J. Am. Chem. Soc. 80, 3161 (1958); Oliveto et al., J. Am. Ohem. Soc. 80, 4431 (1958); U.S. Pat. 3,007,923; Ger. Pat. 1 ,113,690 or Brit. Pat. 869,511. Dexamethasone is commercially available.
  • Budesonide as used herein includes budesonide and its pharmaceutically acceptable salts.
  • Preferred salts of budesonide include its palmitate, laurate, myristate, stearate, oleate, valerate and acetate salts.
  • Budesonide 16,17-butylidenebis(oxy)-11 ,21-dihydroxypregna-1 ,4-diene-3,20- dione, is a well known compound and may be prepared according to U.S. Pat.
  • the nasal spray or nasal drop formulation herein can contain, in addition to the compounds discussed above antimicrobial agents, antioxidants, agents to increase viscosity, isotonic agents, buffers, solubilizing agents, surface active agents and the like.
  • Suitable antimicrobial agents include chlorobutanol, phenylmercuric nitrate, phenyl ethyl alcohol, thimerosal, the quaternary ammonium germicides, such as, benzalkonium chloride, benzethonium chloride or cetylpyridium chloride.
  • Suitable antioxidants include sodium sulfite, sodium ascorbate, oxime sulfate, etc.
  • the preferred isotonic agent is sodium chloride however, other isotonic agents such as dextrose, boric acid and sodium tartrate may be employed.
  • the object of the buffer is to adjust the pH to one compatible with nasal mucous membranes and to stabilize the active ingredient. Ideally the target pH should vary between about 4 and about 6.5. Suitable buffers included phthalate buffers, borate buffers, phosphate buffers, such as HP ⁇ 4 2 7H2PO-r> acetate buffers, such as acetic acid/sodium acetate, a bicarbonate buffer such as CO2/HCO3, or a citrate buffer, such as citric acid/citrate, also it may be adjusted by simply adding an acid such as HCI to achieve the desired acidity.
  • Suitable agents to increase viscosity include polyvinyl alcohol, cellulose derivatives, polyvinylpyrollidone, polysorbates or glycerine.
  • Suitable surface active agents improve abso ⁇ tion by the nasal mucosa and include polyoxyl 40 stearate, polyoxyethylene 50 stearate, polysorbate 80 and octoxynol.
  • concentration of the additives will be in the range as follows:
  • the buffer should be added in sufficient amount to achieve the pH range stated above of about 4.0 to about 6.5.
  • Aerosol formulations and nose drops are prepared as per known techniques.
  • the water employed should be of an appropriate pharmacutical grade of purified water. These formulations should be administered by drop or spray every 4 to 6 hours to obtain the desired relief.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention se rapporte à un pulvérisateur nasal ou à des gouttes nasales pour le traitement de rhinites allergiques comprenant: (a) une quantité efficace d'une antihistamine topique pour soulager les symptômes induits par l'histamine, ladite antihistamine nasale topique étant choisie parmi la lévocabastine, l'azélastine et l'azatadine; (b) une quantité efficace d'un stéroïde à administration topique par voie nasale pour réduire l'inflammation, ledit stéroïde étant choisi parmi la béclométhasone, la flunisolide, la triamcinolone, la dexaméthasone et la budésonide; et (c) de l'eau stérile.
PCT/US1996/010789 1995-06-29 1996-06-25 Combinaison d'antihistamines et de steroides a application topique par voie nasale WO1997001337A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU63924/96A AU6392496A (en) 1995-06-29 1996-06-25 The combination of topical nasal antihistamines and topical nasal steroids

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49681495A 1995-06-29 1995-06-29
US08/496,814 1995-06-29

Publications (1)

Publication Number Publication Date
WO1997001337A1 true WO1997001337A1 (fr) 1997-01-16

Family

ID=23974249

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/010789 WO1997001337A1 (fr) 1995-06-29 1996-06-25 Combinaison d'antihistamines et de steroides a application topique par voie nasale

Country Status (2)

Country Link
AU (1) AU6392496A (fr)
WO (1) WO1997001337A1 (fr)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997046243A1 (fr) * 1996-06-04 1997-12-11 The Procter & Gamble Company Aerosol nasal contenant un steroide intranasal et un antihistaminique
WO1998048839A1 (fr) * 1997-04-30 1998-11-05 Warner-Lambert Company Compositions antiinflammatoires pour application nasale topique
WO2001022955A2 (fr) * 1999-09-30 2001-04-05 Viatris Gmbh & Co. Kg Nouvelle association de loteprednol et de produits antihistaminiques
US6291445B1 (en) 1996-12-05 2001-09-18 Astra Aktiebolag Low dose budesonide formulations and uses thereof
WO2003049770A1 (fr) * 2001-12-05 2003-06-19 Alcon, Inc. Utilisation d'un antagoniste h1 et d'un steroide inoffensif pour traiter la rhinite
GB2389530A (en) * 2002-06-14 2003-12-17 Cipla Ltd Pharmaceutical composition comprising azelastine and steroid
US6686346B2 (en) 1996-12-05 2004-02-03 Astra Aktiebolag Formulation
US6712803B1 (en) * 1999-08-11 2004-03-30 Howard Paritsky Drug dispensing system
WO2004043470A1 (fr) * 2002-11-12 2004-05-27 Alcon, Inc. Utilisation d'un agent anti-allergique et d'un steroide pour traiter une rhinite allergique
US6767901B1 (en) 1999-10-20 2004-07-27 Altana Pharma Ag Ciclesonide contained pharmaceutical composition for application to mucosa
WO2005030331A1 (fr) * 2003-09-26 2005-04-07 Fairfield Clinical Trials, Llc Traitement antihistaminique combine
WO2005037245A2 (fr) * 2003-10-21 2005-04-28 Direct-Haler A/S Medication a administration par voies multiples, servant a traiter une rhinite et un asthme
US6939559B1 (en) 1998-04-21 2005-09-06 Teijin Limited Pharmaceutical composition for application to mucosa
JP2005539044A (ja) * 2002-08-30 2005-12-22 アルタナ　ファルマ　アクチエンゲゼルシャフト アレルギー性鼻炎を治療するためのシクレソニドと抗ヒスタミン剤との組合せ物の使用
WO2006102494A2 (fr) * 2005-03-23 2006-09-28 Elan Pharma International Limited Formulations d'un corticosteroide nanoparticulaire et d'un antihistamine
EP1788816A2 (fr) 1997-11-05 2007-05-23 Sony Corporation Interpolation dans le domaine transformé dans le cadre d'une conversion de résolution vidéo
WO2009067317A2 (fr) * 2007-11-19 2009-05-28 Bausch & Lomb Incorporated Compositions et procédés de modulation de la production de cytokines pro-inflammatoires
US20110038806A1 (en) * 2003-07-29 2011-02-17 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a steroid
WO2011141929A2 (fr) 2010-05-11 2011-11-17 Cadila Healthcare Limited Compositions pharmaceutiques aqueuses de fluticasone et d'olopatadine
WO2012074231A2 (fr) 2010-11-29 2012-06-07 한림제약(주) Composition pharmaceutique comprenant du furoate de mométasone et du chlorhydrate d'azélastine pour une administration nasale
US8383611B1 (en) 1999-10-20 2013-02-26 Nycomed Gmbh Ciclesonide containing aqueous pharmaceutical composition
US9333195B2 (en) 1999-07-14 2016-05-10 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US9737520B2 (en) 2011-04-15 2017-08-22 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
CN107737105A (zh) * 2017-11-28 2018-02-27 贵州云峰药业有限公司 一种鼻腔用盐酸氮卓斯汀组合物喷雾剂及生产工艺
US9919050B2 (en) 2004-11-24 2018-03-20 Meda Pharmaceuticals Inc. Compositions comprising azelastine
US9980959B2 (en) 2004-05-11 2018-05-29 Biolipox Ab Method and composition for treating rhinitis
US10064817B2 (en) 2004-11-24 2018-09-04 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US10085974B2 (en) 2008-03-13 2018-10-02 Almirall, S.A. Dosage and formulation

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BUSSE W.: "NEW DIRECTIONS AND DIMENSIONS IN THE TREATMENT OF ALLERGIC RHINITIS", J.ALLERGY CLIN. IMMUNOL., vol. 82, no. 5, November 1988 (1988-11-01), pages 890 - 900, XP000603998 *
DELAFUENTE J.C., ET AL.: "PHARMACOTHERAPY OF ALLERGIC RHINITIS", CLINICAL PHARMACY, vol. 8, no. 7, July 1989 (1989-07-01), pages 474 - 485, XP000603999 *
HOLLINGSWORTH: "ALLERGIC RHINOCONJUCTIVITIS: CURRENT THERAPY", HOSPITAL PRACTICE, vol. 31, no. 6, 15 June 1996 (1996-06-15), pages 61 - 73, XP000604174 *
HORAK F.: "SEASONAL ALLERGIC RHINITIS", DRUGS, vol. 45, no. 4, 1993, pages 518 - 527, XP000603981 *
LUND V.: "PRACTICAL APPLICATION OF THE INTERNATIONAL CONSENSUS ON THE MANAGEMENT OF RHINITIS", CLINICAL IMMUNOTHERAPEUTICS, vol. 4, no. 4, April 1995 (1995-04-01), pages 270 - 278, XP000604030 *
MEETING OF THE ROYAL BELGIAN SOCIETY FOR ENT, HEAD AND NECK SURGERY, February 1995 (1995-02-01), BRUSSELS *
PURELLO D'AMBROSIO F., ET AL.: "LEVOCABASTINA VERSUS FLUNISOLIDE NEL TRATTAMENTO DELLA RINITE ALLERGICA PERENNE", INTERNISTA, vol. 3, September 1995 (1995-09-01), pages 167 - 170, XP000604083 *
WANG D., ET AL.: "THE ACTIVITY OF RECENT ANTI-ALLERGIC DRUGS IN THE TREATMENT OF SEASONAL ALLERGIC RHINITIS", ACTA OTORHINOLARYNGOL., vol. 50, no. 1, January 1996 (1996-01-01), pages 25 - 32, XP000604028 *

Cited By (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997046243A1 (fr) * 1996-06-04 1997-12-11 The Procter & Gamble Company Aerosol nasal contenant un steroide intranasal et un antihistaminique
US6986904B2 (en) 1996-12-05 2006-01-17 Astrazeneca Ab Formulation
US6686346B2 (en) 1996-12-05 2004-02-03 Astra Aktiebolag Formulation
US6291445B1 (en) 1996-12-05 2001-09-18 Astra Aktiebolag Low dose budesonide formulations and uses thereof
WO1998048839A1 (fr) * 1997-04-30 1998-11-05 Warner-Lambert Company Compositions antiinflammatoires pour application nasale topique
EP1788816A2 (fr) 1997-11-05 2007-05-23 Sony Corporation Interpolation dans le domaine transformé dans le cadre d'une conversion de résolution vidéo
BG64919B1 (bg) * 1998-04-21 2006-09-29 Teijin Ltd. Фармацевтичен състав за прилагане върху мукоза
US7235247B2 (en) 1998-04-21 2007-06-26 Teijin Pharma Limited Pharmaceutical composition for application to mucosa
US6939559B1 (en) 1998-04-21 2005-09-06 Teijin Limited Pharmaceutical composition for application to mucosa
US9333195B2 (en) 1999-07-14 2016-05-10 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
USRE46417E1 (en) 1999-07-14 2017-05-30 Almirall, S.A. Quinuclidine derivatives and their use as muscarinic M3 receptor ligands
US9687478B2 (en) 1999-07-14 2017-06-27 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US10588895B2 (en) 1999-07-14 2020-03-17 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US10034867B2 (en) 1999-07-14 2018-07-31 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US6712803B1 (en) * 1999-08-11 2004-03-30 Howard Paritsky Drug dispensing system
US7022687B1 (en) 1999-09-30 2006-04-04 Asta Medica Ag Combination of loteprednol and antihistamines
WO2001022955A3 (fr) * 1999-09-30 2001-05-17 Asta Medica Ag Nouvelle association de loteprednol et de produits antihistaminiques
JP2012001558A (ja) * 1999-09-30 2012-01-05 Meda Pharma Gmbh & Co Kg ロテプレドノールと抗ヒスタミン薬の新規な組み合わせ物
WO2001022955A2 (fr) * 1999-09-30 2001-04-05 Viatris Gmbh & Co. Kg Nouvelle association de loteprednol et de produits antihistaminiques
JP2003510275A (ja) * 1999-09-30 2003-03-18 フィアトリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト ロテプレドノールと抗ヒスタミン薬の新規な組み合わせ物
US6767901B1 (en) 1999-10-20 2004-07-27 Altana Pharma Ag Ciclesonide contained pharmaceutical composition for application to mucosa
US8383611B1 (en) 1999-10-20 2013-02-26 Nycomed Gmbh Ciclesonide containing aqueous pharmaceutical composition
WO2003049770A1 (fr) * 2001-12-05 2003-06-19 Alcon, Inc. Utilisation d'un antagoniste h1 et d'un steroide inoffensif pour traiter la rhinite
US8937057B2 (en) 2002-06-14 2015-01-20 Cipla Limited Combination of azelastine and mometasone for nasal administration
AU2009243422C1 (en) * 2002-06-14 2014-01-09 Cipla Limited Combination of azelastine and steroids
EP2075000B1 (fr) 2002-06-14 2015-07-22 Cipla Limited Combinaison d'azélastine et du ciclésonide
GB2389530B (en) * 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
AU2009243422B2 (en) * 2002-06-14 2012-03-29 Cipla Limited Combination of azelastine and steroids
US9901585B2 (en) 2002-06-14 2018-02-27 Cipla Limited Combination of azelastine and fluticasone for nasal administration
US8933060B2 (en) 2002-06-14 2015-01-13 Cipla Limited Combination of azelastine and ciclesonide for nasal administration
EP2072051A1 (fr) * 2002-06-14 2009-06-24 Cipla Ltd. Combinaison d'azélastine et de mométasone
EP2075000A1 (fr) * 2002-06-14 2009-07-01 Cipla Ltd. Combinaison d'azélastine et du ciclésonide
US9259428B2 (en) 2002-06-14 2016-02-16 Cipla Limited Combination of azelastine and fluticasone for nasal administration
AU2003244799B2 (en) * 2002-06-14 2009-09-10 Cipla Limited Combination of azelastine and steroids
KR101301558B1 (ko) * 2002-06-14 2013-09-04 씨아이피엘에이 엘티디. 아젤라스틴 및 스테로이드의 조합
KR101301061B1 (ko) * 2002-06-14 2013-08-28 씨아이피엘에이 엘티디. 아젤라스틴 및 스테로이드의 조합
GB2389530A (en) * 2002-06-14 2003-12-17 Cipla Ltd Pharmaceutical composition comprising azelastine and steroid
US8318709B2 (en) 2002-06-14 2012-11-27 Cipla Limited Combination of azelastine and mometasone for nasal administration
US8304405B2 (en) 2002-06-14 2012-11-06 Cipla Limited Combination of azelastine and ciclesonide for nasal administration
AU2009243420B2 (en) * 2002-06-14 2012-10-11 Cipla Limited Combination of azelastine and steroids
US8163723B2 (en) 2002-06-14 2012-04-24 Cipla Limited Combination of azelastine and steroids
WO2003105856A1 (fr) * 2002-06-14 2003-12-24 Cipla Limited Association d'azelastine et de steroides
KR101119895B1 (ko) * 2002-06-14 2012-02-22 씨아이피엘에이 엘티디. 아젤라스틴 및 스테로이드의 조합
JP2005539044A (ja) * 2002-08-30 2005-12-22 アルタナ　ファルマ　アクチエンゲゼルシャフト アレルギー性鼻炎を治療するためのシクレソニドと抗ヒスタミン剤との組合せ物の使用
US8486923B2 (en) 2002-08-30 2013-07-16 Takeda Gmbh Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
US7879832B2 (en) 2002-08-30 2011-02-01 Nycomed Gmbh Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
JP2011021043A (ja) * 2002-08-30 2011-02-03 Nycomed Gmbh アレルギー性鼻炎を治療するためのシクレソニドと抗ヒスタミン剤との組合せ物の使用
JP4746318B2 (ja) * 2002-08-30 2011-08-10 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング シクレソニドと抗ヒスタミン剤との組合せ物を含有するアレルギー性鼻炎の治療用医薬組成物
EP2295062A1 (fr) 2002-08-30 2011-03-16 Nycomed GmbH Utilisation de la combinaison de ciclesonide et des antihistamines pour le traitement de rhinite allergique
CN1297275C (zh) * 2002-11-12 2007-01-31 爱尔康公司 抗过敏剂和类固醇用于治疗过敏性鼻炎的用途
WO2004043470A1 (fr) * 2002-11-12 2004-05-27 Alcon, Inc. Utilisation d'un agent anti-allergique et d'un steroide pour traiter une rhinite allergique
JP2006508138A (ja) * 2002-11-12 2006-03-09 アルコン，インコーポレイテッド アレルギー性鼻炎を処置するための抗アレルギー剤およびステロイドの使用
US20110038806A1 (en) * 2003-07-29 2011-02-17 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a steroid
WO2005030331A1 (fr) * 2003-09-26 2005-04-07 Fairfield Clinical Trials, Llc Traitement antihistaminique combine
WO2005037245A2 (fr) * 2003-10-21 2005-04-28 Direct-Haler A/S Medication a administration par voies multiples, servant a traiter une rhinite et un asthme
WO2005037245A3 (fr) * 2003-10-21 2005-08-11 Direct Haler As Medication a administration par voies multiples, servant a traiter une rhinite et un asthme
US9980959B2 (en) 2004-05-11 2018-05-29 Biolipox Ab Method and composition for treating rhinitis
US9919050B2 (en) 2004-11-24 2018-03-20 Meda Pharmaceuticals Inc. Compositions comprising azelastine
US10064817B2 (en) 2004-11-24 2018-09-04 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US8003127B2 (en) 2005-03-23 2011-08-23 Elan Pharma International Limited Nanoparticulate corticosteroid and antihistamine formulations methods of making, and methods of administering thereof
WO2006102494A2 (fr) * 2005-03-23 2006-09-28 Elan Pharma International Limited Formulations d'un corticosteroide nanoparticulaire et d'un antihistamine
JP2008534509A (ja) * 2005-03-23 2008-08-28 エラン ファーマ インターナショナル リミテッド ナノ粒子副腎皮質ステロイドおよび抗ヒスタミン薬の製剤
WO2006102494A3 (fr) * 2005-03-23 2007-01-25 Elan Pharma Int Ltd Formulations d'un corticosteroide nanoparticulaire et d'un antihistamine
WO2009067317A2 (fr) * 2007-11-19 2009-05-28 Bausch & Lomb Incorporated Compositions et procédés de modulation de la production de cytokines pro-inflammatoires
WO2009067317A3 (fr) * 2007-11-19 2009-08-06 Bausch & Lomb Compositions et procédés de modulation de la production de cytokines pro-inflammatoires
US10085974B2 (en) 2008-03-13 2018-10-02 Almirall, S.A. Dosage and formulation
US11000517B2 (en) 2008-03-13 2021-05-11 Almirall, S.A. Dosage and formulation
WO2011141929A2 (fr) 2010-05-11 2011-11-17 Cadila Healthcare Limited Compositions pharmaceutiques aqueuses de fluticasone et d'olopatadine
US8859531B2 (en) 2010-11-29 2014-10-14 Hanlim Pharmaceutical Co., Ltd Pharmaceutical composition including mometasone furoate and azelastine hydrochloride for nasal administration
WO2012074231A2 (fr) 2010-11-29 2012-06-07 한림제약(주) Composition pharmaceutique comprenant du furoate de mométasone et du chlorhydrate d'azélastine pour une administration nasale
US9737520B2 (en) 2011-04-15 2017-08-22 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
CN107737105A (zh) * 2017-11-28 2018-02-27 贵州云峰药业有限公司 一种鼻腔用盐酸氮卓斯汀组合物喷雾剂及生产工艺

Also Published As

Publication number Publication date
AU6392496A (en) 1997-01-30

Similar Documents

Publication Publication Date Title
WO1997001337A1 (fr) Combinaison d'antihistamines et de steroides a application topique par voie nasale
US8486923B2 (en) Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
US20110086023A1 (en) Combination antihistamine medication
US20080194468A1 (en) Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
US20040097474A1 (en) Use of an anti-allergy agent and a steroid to treat nasal conditions
US20060228306A1 (en) Combination antihistamine and steroid medication
EP0780127A1 (fr) Pulvérisateur nasale contenant un stéréoide et un antihistamine
US4945089A (en) Use of tetrahydrocortexolone to prevent elevations in intraocular pressure caused by corticosteroids
US20090022671A1 (en) Treatment methods
WO1997001341A1 (fr) Combinaison d'agents de stabilisation de mastocytes nasaux topiques avec des steroides nasaux topiques
JP5278313B2 (ja) 輸送体増強コルチコステロイド活性
Schenkel Features of mometasone furoate nasal spray and its utility in the management of allergic rhinitis
Tse et al. Corticosteroid aerosols in the treatment of asthma
Al-Mohaimeid A parallel-group comparison of budesonide and beclomethasone dipropionate for the treatment of perennial allergic rhinitis in adults
WO1997001340A1 (fr) Combinaison d'antihistamines nasales topiques et de stabilisateurs de mastocytes topiques par voie nasale
Martin Pharmacology of nasal medications: an update
CA2241879A1 (fr) Utilisation d'inhibiteurs de la phosphodiesterase 4 pour traiter la rhinite allergique
Steyn Triamcinolone acetonide aqueous...
Kaulbach et al. 64 Effects of nedocrumil sodium on allergen-induced rhinitis in humans
Drouin et al. 63 Multicentre clinical evaluation of the efficacy and safety of noberastine, a new H1-antagonist, in seasonal allergic rhinitis
NZ616149A (en) Nasal pharmaceutical formulation comprising fluticasone
MXPA06008935A (en) Treatment of rhinitis with anticholinergics alone in combination with antihistamines phosphodiesterase 4 inhibitors, or corticosteroids

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA